Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Net Cash Flow (2016 - 2025)

Avanos Medical (AVNS) has disclosed Net Cash Flow for 13 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 18.34% to $18.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.9 million through Dec 2025, down 195.02% year-over-year, with the annual reading at -$22.9 million for FY2025, 195.02% down from the prior year.
  • Net Cash Flow hit $18.7 million in Q4 2025 for Avanos Medical, up from -$19.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $26.9 million in Q3 2023 to a low of -$32.9 million in Q1 2023.
  • Historically, Net Cash Flow has averaged -$790000.0 across 5 years, with a median of -$2.9 million in 2021.
  • Biggest five-year swings in Net Cash Flow: soared 1787.5% in 2022 and later tumbled 404.35% in 2023.
  • Year by year, Net Cash Flow stood at $21.6 million in 2021, then crashed by 68.06% to $6.9 million in 2022, then crashed by 404.35% to -$21.0 million in 2023, then soared by 209.05% to $22.9 million in 2024, then fell by 18.34% to $18.7 million in 2025.
  • Business Quant data shows Net Cash Flow for AVNS at $18.7 million in Q4 2025, -$19.5 million in Q3 2025, and -$9.6 million in Q2 2025.